Best AI Tools for Oncologists 2025: Treatment Planning and Clinical Decision Support

Oncology is one of the most data-intensive specialties in medicine. Every treatment decision requires integrating radiology images, genomic sequencing results, pathology slides, clinical trial data, and published literature — often under extreme time pressure. Artificial intelligence is now transforming how oncologists handle this complexity.

In 2025, AI tools for oncologists have moved well beyond pilot studies. These platforms are actively deployed in leading cancer centers worldwide, reducing diagnostic turnaround times, flagging rare mutation patterns, and matching patients to appropriate clinical trials automatically. This guide reviews the most impactful AI tools available today for oncology practice.

Why Oncologists Need AI Tools in 2025

Cancer diagnosis and treatment planning have become extraordinarily complex. The average oncologist must stay current with thousands of clinical trials, rapidly evolving targeted therapies, immunotherapy protocols, and biomarker-driven treatment pathways. Human cognitive limits make errors inevitable without decision support.

Key challenges AI addresses in oncology:

• Information overload: Over 200,000 oncology papers are published annually. AI can synthesize relevant literature for specific tumor types and patient profiles in seconds.
• Diagnostic variability: Pathologist agreement rates on some cancer subtypes can be as low as 75%. AI pathology tools consistently achieve 90%+ accuracy on trained subtypes.
• Treatment matching: Genomic sequencing produces thousands of variants per patient. AI tools identify actionable mutations and matched therapies automatically.
• Workflow bottlenecks: Radiology and pathology departments face chronic backlogs. AI pre-screening and triaging reduces time-to-diagnosis by 30–60% in many settings.

Best AI Tools for Oncologists in 2025

1. Tempus AI – Genomic Intelligence Platform

Tempus is widely considered the most comprehensive AI platform in clinical oncology. The platform combines one of the largest multimodal oncology databases with advanced AI models that generate actionable insights from molecular profiling, imaging, and clinical records.

Key features:

• Whole exome and whole transcriptome sequencing with AI-driven variant interpretation
• Matching engine that connects patients to relevant clinical trials across 1,000+ ongoing studies
• TIME (Tempus Intelligent Medical Evidence) model for treatment outcome prediction
• Radiology and pathology AI modules integrated into a single dashboard
• EHR integrations with Epic, Cerner, and major hospital systems

Best for: Academic medical centers and large oncology practices seeking end-to-end molecular profiling with integrated decision support.

Pricing: Enterprise contracts; typical per-test costs range $2,500–$7,500 depending on panel scope.

2. Paige.AI – FDA-Cleared Computational Pathology

Paige.AI received the first-ever FDA de novo authorization for an AI-based cancer detection system in pathology. Their Paige Prostate product detects prostate cancer in whole-slide images with sensitivity exceeding that of expert pathologists in large validation studies.

Key features:

• FDA-cleared prostate cancer detection and grading assistance
• Breast, lung, and colorectal cancer AI models (CE marked in Europe)
• Whole-slide image analysis at diagnostic resolution
• Integrated with major laboratory information systems (LIS)
• Uncertainty quantification — the AI flags cases where confidence is lower for expert prioritization

Best for: Pathology departments handling high slide volumes who want FDA-cleared AI assistance for prostate and expanding cancer types.

3. PathAI – Pathology AI for Research and Clinical Use

PathAI partners with pharmaceutical companies and health systems to develop AI-powered pathology tools. Their AISight platform enables precision pathology at scale, with particular strength in biomarker quantification and clinical trial endpoint assessment.

Key features:

• Automated tumor microenvironment analysis (TIL scoring, PD-L1 quantification)
• Companion diagnostic development support
• Clinical trial endpoint standardization using AI pathology
• Real-world evidence generation from pathology archives

Best for: Oncology research teams and pharma partners focused on biomarker development and clinical trial support.

4. IBM Watson for Oncology (Now: Merge with Merative)

Originally pioneered as Watson for Oncology at Memorial Sloan Kettering, the platform (now evolving under Merative) provides evidence-based treatment recommendations aligned with major guidelines including NCCN, ESMO, and ASCO. It reads the patient’s medical history and tumor characteristics and surfaces ranked treatment options with evidence citations.

Key features:

• Natural language processing of unstructured clinical notes
• Guideline-concordant treatment recommendations
• Evidence trail with PubMed citations for each recommendation
• Deployment in 50+ countries with localized guideline support

5. DeepMind Med-Gemini – Multimodal Clinical Reasoning

Google DeepMind’s Med-Gemini represents the frontier of general-purpose medical AI. In 2024-2025 evaluations, Med-Gemini demonstrated performance at or above specialist physician level on several oncology benchmarks, including radiology interpretation, pathology classification, and treatment guideline Q&A.

Key features:

• Multimodal input: text, imaging, genomic data, lab values simultaneously
• Long-context reasoning over entire patient records
• Real-time literature synthesis for rare tumor types
• Available via Google Cloud Healthcare API for enterprise integration

6. Viz.ai – Oncology Imaging AI

While Viz.ai is best known for stroke detection, its oncology modules are expanding rapidly. The platform uses AI to detect and triage suspicious findings in CT, MRI, and PET scans, routing urgent cases to the right specialist faster.

Key features:

• Lung nodule detection and Lung-RADS risk stratification
• Incidental finding detection across body imaging
• Care coordination workflow built around AI alerts
• FDA 510(k) cleared for multiple imaging indications

7. Flatiron Health – Real-World Evidence and Clinical Analytics

Acquired by Roche, Flatiron Health operates the largest oncology-specific real-world data network in the US. Their OncoEMR and analytics platform give oncologists and researchers access to structured data from 800+ cancer clinics, enabling outcome benchmarking and treatment pattern analysis.

Best for: Oncology practices participating in research networks or seeking outcome benchmarking against national cohorts.

AI for Radiation Oncology: Treatment Planning Tools

Radiation oncology has seen some of the most dramatic AI advances, with tools that automate the most time-consuming parts of treatment planning.

Varian Ethos – Adaptive AI Radiotherapy

Varian’s Ethos system uses AI to generate daily adaptive treatment plans in under 15 minutes, accounting for tumor and organ changes between fractions. Previously, adaptive planning required hours of manual work.

Elekta MOSAIQ with AI Contouring

Elekta’s AI auto-segmentation tools can delineate tumor volumes and organs-at-risk from CT and MRI scans with accuracy comparable to expert radiation oncologists, reducing contouring time from hours to minutes.

RaySearch RayStation

RayStation incorporates deep learning models for plan optimization and auto-contouring across multiple cancer sites, with particular strength in head and neck and prostate cases.

AI for Clinical Trial Matching

One of the highest-value applications of AI in oncology is matching patients to clinical trials they may otherwise miss. Studies show only 5% of eligible cancer patients enroll in clinical trials — largely due to the complexity of identifying eligibility.

Leading tools:

• Tempus NEXT: AI-powered trial matching integrated with molecular data
• Mendel.ai: NLP-based trial matching that reads clinical notes to identify eligible patients
• TrialSpark: Streamlines patient recruitment for trial sponsors with AI eligibility screening
• Deep 6 AI: Retrospective cohort identification from EHR data for trial feasibility

Key Takeaways

How to Evaluate AI Tools for Your Oncology Practice

When selecting an AI tool, oncologists should consider:

• Regulatory clearance: Is the tool FDA cleared or CE marked for your intended use case?
• Validation evidence: Were validation studies conducted on patient populations similar to yours?
• EHR integration: Does it connect to your existing Epic, Cerner, or other system?
• Workflow fit: Does it reduce or add steps to your existing workflow?
• Explainability: Can the AI explain why it made a recommendation in a way you can convey to patients?
• Data governance: How is patient data protected? Is it used for model training?

Frequently Asked Questions

Is AI replacing oncologists?

No. AI tools in oncology are decision support systems designed to augment oncologist expertise, not replace clinical judgment. They process large volumes of data faster than humans and surface relevant insights — but treatment decisions remain with the physician and care team.

Are AI oncology tools FDA approved?

Several tools have FDA clearance. Paige.AI’s prostate cancer detection received the first-ever FDA de novo authorization for AI-based cancer detection in digital pathology. Viz.ai’s imaging tools hold multiple 510(k) clearances. However, many AI tools operate as clinical decision support (not regulated medical devices) under current FDA frameworks.

How accurate are AI pathology tools?

In large validation studies, top AI pathology tools achieve 90–96% accuracy on trained cancer subtypes, often matching or exceeding expert pathologist agreement rates. Paige Prostate demonstrated higher sensitivity than 11 of 15 participating pathologists in its pivotal study.

What is the cost of AI tools for oncology practices?

Costs vary widely. Genomic profiling AI platforms like Tempus typically charge per test ($2,500–$7,500). Imaging AI tools often use subscription or per-scan pricing. Radiation oncology AI (Ethos, RayStation) is bundled with hardware/software system purchases. Most vendors offer pilot programs for new customers.

Can small oncology practices use these tools?

Yes, increasingly so. Cloud-based tools like Tempus, Mendel.ai, and many imaging AI platforms are accessible to community oncology practices without requiring large IT infrastructure. Some tools integrate directly with widely used EHR systems, making adoption relatively straightforward.

How do AI tools handle rare cancers?

This is an acknowledged limitation. AI models trained predominantly on common cancers (breast, lung, colorectal, prostate) may have limited performance on rare tumor types. Tools like Med-Gemini, which can synthesize literature in real time, are better suited for rare cancer cases where training data is limited.